SCHEMBL4207255

SCHEMBL4207255

Cc1c(NC(=O)N[C@H]2CC[C@@H](Nc3nc(N(C)C)c4ccccc4n3)CC2)cccc1[N+](=O)[O-]

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 14/20 0.62
ADRA2A P08913 13/20 0.62
KMT2A Q03164 2/20 0.57
HTR1A P08908 1/20 0.52
ADRA1A P35348 1/20 0.52
HRH1 P35367 1/20 0.52
HTR2B P41595 1/20 0.52
NPY5R Q15761 1/20 0.52
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.43
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4207259 1.00 MCHR1 (0.62) MCHR1ADRA2AKMT2AHTR1AADRA1A
SCHEMBL4028461 0.93 MCHR1 (0.63) MCHR1ADRA2AKMT2AHTR1AADRA1A
SCHEMBL4028465 0.93 MCHR1 (0.63) MCHR1ADRA2AKMT2AHTR1AADRA1A
SCHEMBL5530907 0.90 MCHR1 (0.54) MCHR1ADRA2AKMT2AHTR1AADRA1A
SCHEMBL5534544 0.90 MCHR1 (0.54) MCHR1ADRA2AKMT2AHTR1AADRA1A
SCHEMBL4209828 0.88 MCHR1 (0.62) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL4205914 0.88 MCHR1 (0.62) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL4031797 0.86 MCHR1 (0.62) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL5526800 0.86 MCHR1 (0.62) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL5521770 0.86 MCHR1 (0.59) MCHR1ADRA2AKMT2AHTR1AADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611109-A4 NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO LTD (JP) 2009-06-24 EP claimed
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US claimed
JP-2006522109-A 2006-09-28 JP claimed
EP-1611109-A1 NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO., LTD (JP) 2006-01-04 EP claimed
WO-2004087680-A1 NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO., LTD. (JP) 2004-10-14 WO claimed
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 MCHR1 1/4885ADRA2A 103/4885KMT2A 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.